Irinotecan
Small molecule targets TOP1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ONIVYDE | — | 2024-02-13 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | CAMPTOSAR | — | 1998-10-22 – 2004-06-24 | fda.gov ↗ |
| Approved | US (FDA) | CAMPTOSAR | — | 1996-06-14 | fda.gov ↗ |
Trials 1,239 · started per year
Also used as a comparator or background therapy in 593 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06011772 Background | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03554707 Background | Jun 2022 | central nervous system cancer | SynerGene Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 1105 trials | ||||||
| Phase 1 | NCT07671339 Background | Jun 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07619313 Background | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07314385 Background | Jan 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06995872 Background | Oct 2025 → Jun 2028 expected | neuroblastoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT07024615 Background | Oct 2025 → Jan 2028 expected | pancreatic ductal adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06396091 Background | Sep 2025 → Jul 2026 overdue | pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06896188 Background | Sep 2025 → Sep 2027 expected | pancreatic adenocarcinoma | Anwaar Saeed | Recruiting | No outcome recorded |
| Phase 1 | NCT06867822 Background | Jul 2025 → Jul 2027 expected | colorectal cancer | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1 | NCT06974110 Background | Jul 2025 → Nov 2027 expected | colorectal cancer, endometrial cancer, gastric cancer, metastatic neoplasm | MOMA Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07027748 Background | Jun 2025 → Jul 2027 expected | neuroblastoma | Steven DuBois, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06648434 Background | Jun 2025 → Jun 2027 expected | pancreatic ductal adenocarcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT06963502 Background | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07543744 Background | Apr 2025 → May 2026 overdue | colorectal cancer | R-Pharm | Recruiting | No outcome recorded |
| Phase 1 | NCT06607185 Background | Oct 2024 → Jan 2030 expected | colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06509906 Background | Oct 2024 → Dec 2025 | neoplasm | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06586515 Background | Sep 2024 → Mar 2029 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06360354 Background | May 2024 → Oct 2026 expected | digestive system carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06278454 Background | Jan 2024 → Dec 2027 expected | malignant exocrine pancreas neoplasm, metastatic malignant neoplasm in the lymph nodes | Chengdu New Radiomedicine Technology Co. LTD. | Recruiting | No outcome recorded |
| Phase 1 | NCT05400603 Background | Nov 2023 → Dec 2026 expected | neuroblastoma, osteosarcoma | Emory University | Recruiting | No outcome recorded |
| Phase 1 | NCT06006273 Background | Aug 2023 → Dec 2026 expected | refractory malignant neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05070104 Background | Mar 2023 → Mar 2024 | — | Cornerstone Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT05546853 Background | Mar 2023 → Dec 2024 | pancreatic ductal adenocarcinoma | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 1 | NCT04525014 Background | Jan 2023 → Jul 2024 | brain cancer, childhood malignant neoplasm | EpicentRx, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05421897 Background | Nov 2022 → Jan 2026 overdue | neuroblastoma | Children's Hospital Los Angeles | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05417386 Background | Aug 2022 → Jul 2023 | pancreatic adenocarcinoma | Colin D. Weekes, M.D., PhD | Terminated | No outcome recorded |
| Phase 1 | NCT05382559 Background | Jun 2022 → Dec 2028 expected | cancer | Astellas Pharma Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT05365581 Background | Jun 2022 → May 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05087992 Background | Nov 2021 → Oct 2023 | digestive system cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04929223 Background | Oct 2021 → Aug 2030 expected | colorectal cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT06532344 Background | Jul 2021 → Dec 2026 expected | malignant pancreatic neoplasm | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04158349 Background | Mar → May 2021 | appendix cancer, peritoneal carcinoma | University of Utah | Terminated | No outcome recorded |
| Phase 1 | NCT04292743 Background | Dec 2020 → Jan 2023 | pancreatic ductal adenocarcinoma | Georgetown University | Completed | No outcome recorded |
| Phase 1 | NCT04627142 Background | Nov 2020 → Jan 2022 | colorectal cancer | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT04553692 Background | Sep 2020 → Jan 2025 | acute myeloid leukemia, chondrosarcoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, colorectal cancer | IGM Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04329494 Background | Aug 2020 → Jan 2028 expected | appendix carcinoma, gastric carcinoma, metastatic malignant neoplasm, ovarian carcinoma +2 | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04299880 Background | Feb 2020 → May 2021 | — | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03885284 Background | Jul 2019 → May 2022 | pancreatic adenocarcinoma | Georgetown University | Completed | No outcome recorded |
| Phase 1 | NCT03883919 Background | Jul 2019 → Mar 2021 | malignant pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT03798626 Background | May 2019 → Mar 2023 | colorectal cancer, gastroesophageal cancer, renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03872947 Background | Apr 2019 → Jun 2026 overdue | cholangiocarcinoma, colorectal cancer, fallopian tube cancer, gastric cancer +5 | Toray Industries, Inc | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04088604 Comparator | Feb 2019 → Dec 2021 | neoplasm | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03692429 Background | Nov 2018 → Nov 2021 overdue | colorectal cancer | Celyad Oncology SA | Recruiting | No outcome recorded |
| Phase 1 | NCT03715933 Background | Oct 2018 → Dec 2028 expected | Ewing sarcoma, colorectal adenocarcinoma | Inhibrx Biosciences, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT03597581 Background | Jun 2018 → Mar 2025 | colorectal carcinoma, gastric cancer | Inspirna, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03503604 Background | May 2018 → Jan 2019 | cancer | SuZhou Stainwei Biotech Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03323034 Background | Jan 2018 → Sep 2021 | central nervous system neoplasm, lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT03250832 Background | Aug 2017 → Jun 2022 | neoplasm | Tesaro, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03082209 Background | Mar 2017 → Jan 2022 | cancer, hematopoietic and lymphoid cell neoplasm | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03253133 Background | May 2016 → Oct 2020 | colorectal cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1 | NCT02720068 Background | May 2016 → Mar 2024 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02726334 Background | Mar 2016 → Dec 2017 | colorectal cancer | Bionomics Limited | Terminated | No outcome recorded |
| Phase 1 | NCT02641873 Background | Dec 2015 → Dec 2016 | colorectal cancer | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02588105 Background | Nov 2015 → Sep 2019 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02596503 Background | Oct 2015 → Apr 2019 | refractory malignant neoplasm | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT02592395 Background | Oct 2015 → Oct 2017 | pancreatic adenocarcinoma | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded |
| Phase 1 | NCT02548169 Comparator | Aug 2015 → Apr 2017 | malignant pancreatic neoplasm | Baylor Research Institute | Terminated | No outcome recorded |
| Phase 1 | NCT02453464 Background | Aug 2015 → Dec 2016 | colorectal cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02482441 Background | Jul 2015 → Jan 2018 | refractory malignant neoplasm | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02419495 Background | Jun 2015 → Sep 2024 | cutaneous melanoma, fallopian tube carcinoma, metastatic malignant neoplasm, metastatic melanoma +5 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02392793 Comparator | Mar 2015 → Feb 2019 | childhood malignant neoplasm | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02231723 Background | Aug 2014 → Jun 2020 | pancreatic adenocarcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02387138 Background | Apr 2014 → Jun 2018 | digestive system cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1 | NCT02033551 Background | Dec 2013 → Sep 2016 | breast cancer, colorectal cancer, gastric cancer, lung cancer +1 | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02021422 Background | Dec 2013 → Dec 2017 | pancreatic ductal adenocarcinoma | Baylor Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01930552 Background | Sep 2013 → Dec 2014 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01822613 Comparator | Jul 2013 → Jun 2016 | esophageal squamous cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01999270 Background | Apr 2013 → May 2016 | ganglioglioma, ganglioneuroma, glioblastoma, mixed glioma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01835041 Background | Apr 2013 → Feb 2017 | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01803282 Background | Mar 2013 → Apr 2019 | breast cancer, colorectal cancer, gastroesophageal cancer, non-small cell lung carcinoma +1 | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01787500 Background | Feb 2013 → Jan 2022 | colorectal cancer, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02395068 Background | Nov 2012 → Nov 2014 | cancer | Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01653470 Background | Oct 2012 → May 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01528046 Background | Sep 2012 → Sep 2019 | cancer, primary brain neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01576692 Background | Apr 2012 → Oct 2014 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01520389 Background | Jan 2012 → Dec 2015 | colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01485744 Background | Dec 2011 → Nov 2019 | malignant pancreatic neoplasm | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01472016 Background | Oct 2011 → Apr 2017 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01205022 Background | Apr 2011 → Jan 2014 | rectal cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01286818 Background | Feb 2011 → Feb 2012 | colorectal carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01296763 Background | Jan 2011 → Jan 2014 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT01141244 Background | Jun 2010 → Nov 2013 | childhood malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01124630 Background | May 2010 → Jul 2013 | colorectal cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT00960063 Background | Nov 2009 → Dec 2010 | bone cancer, kidney neoplasm, neuroblastoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01009073 Background | Oct 2009 → Jun 2013 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT00719199 Background | Jan 2009 → Apr 2011 | colorectal cancer | EMD Serono | Terminated | No outcome recorded |
| Phase 1 | NCT00786669 Background | Oct 2008 → Nov 2012 | cancer | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT00497497 Background | Oct 2007 → Sep 2010 | colorectal cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00479583 Comparator | Sep 2007 → Apr 2010 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00540943 Background | Jul 2007 → May 2010 | colorectal cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00473616 Background | May 2007 → Jan 2011 | high grade malignant neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00509353 Background | Jan 2007 → Oct 2010 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT00671372 Background | Jul 2006 → Mar 2012 | colorectal cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00507091 Background | Aug 2005 → May 2006 | adenocarcinoma, colorectal cancer, metastatic malignant neoplasm | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00110357 Comparator | Aug 2005 → Mar 2008 | refractory malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00101270 Background | Mar 2005 → Sep 2007 | Burkitt lymphoma, Ewing sarcoma/peripheral primitive neuroectodermal tumor, Hodgkins lymphoma, cerebellar astrocytoma +19 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00502567 Background | Jan 2005 → Nov 2007 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00101894 Background | Dec 2004 → Apr 2010 | colon carcinoma, rectal carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00079352 Background | Apr 2004 → Oct 2007 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00220649 Background | Mar 2004 → ? | pancreatic neoplasm | St. Luke's-Roosevelt Hospital Center | Completed | No outcome recorded |
| Phase 1 | NCT00346801 Background | Sep 2003 → Oct 2012 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00249977 Background | Apr 2003 → Aug 2007 | cancer | University of New Mexico | Completed | No outcome recorded |
| Phase 1 | NCT00042874 Background | May 2002 → Jan 2009 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00006485 Background | Sep 2000 → Dec 2003 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003742 Background | Oct 1998 → Aug 2001 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003484 Background | Sep 1997 → Nov 2003 | central nervous system neoplasm, neuroblastoma | Darell D. Bigner, MD, PhD | Completed | No outcome recorded |
| Phase 1/278 trials | ||||||
| Phase 1/2 | NCT07705919 Background | Sep 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | Ohio State University Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07678593 Background | Sep 2026 → Nov 2027 expected | pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07346157 Background | Jul 2026 → Mar 2031 expected | childhood medulloblastoma | Sabine Mueller, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07391566 Background | Mar 2026 → Dec 2028 expected | colorectal cancer | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07214298 Background | Feb 2026 → Feb 2028 expected | pancreatic ductal adenocarcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07141771 Background | Dec 2025 → Jun 2030 expected | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07155200 Background | Dec 2025 → Jul 2028 expected | small cell lung carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07284277 Background | Oct 2025 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06620302 Background | Jun 2025 → Dec 2031 expected | childhood malignant neoplasm, fibrolamellar hepatocellular carcinoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06936527 Background | May 2025 → Apr 2028 expected | colorectal cancer | NovaOnco Therapeutics Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07204574 Background | May → Dec 2025 overdue | — | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06888648 Background | Apr 2025 → Apr 2027 expected | malignant pancreatic neoplasm | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07056777 Background | Mar 2025 → Apr 2027 expected | digestive system cancer | Zhejiang Doer Biologics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06483555 Comparator | Feb 2025 → Aug 2027 expected | basal cell neoplasm, pancreatic adenocarcinoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07334301 Background | Nov 2024 → Dec 2030 expected | neuroblastoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06541262 Background | Oct 2024 → Nov 2030 expected | Ewing sarcoma, liposarcoma, neuroblastoma, osteosarcoma +1 | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06577376 Comparator | Aug 2024 → Aug 2026 overdue | gastroesophageal adenocarcinoma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06370754 Background | Apr 2024 → Apr 2026 overdue | malignant pancreatic neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05652686 Background | Sep 2023 → Dec 2027 expected | digestive system neuroendocrine neoplasm, large cell neuroendocrine carcinoma, prostate neuroendocrine neoplasm, small cell lung carcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05926206 Background | Jul 2023 → Jan 2027 | pancreatic adenocarcinoma | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05846867 Background | May 2023 → May 2026 overdue | colorectal cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05824455 Background | Mar → Sep 2023 | cancer | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05731518 Background | Feb 2023 → Sep 2025 | small cell lung carcinoma | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05721872 Comparator | Feb → Aug 2023 | colorectal cancer | Nazarbayev University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05419479 Comparator | Nov 2022 → May 2026 | pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma | James Cleary, MD, PhD | Suspended | No outcome recorded |
| Phase 1/2 | NCT05585320 Background | Oct 2022 → Jun 2026 overdue | cutaneous melanoma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Immuneering Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05251038 Background | Sep 2022 → Jan 2023 | malignant pancreatic neoplasm | Devalingam Mahalingam | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05522738 Background | Aug 2022 → Dec 2024 | colorectal cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05379595 Comparator | Jul 2022 → Apr 2027 expected | colorectal cancer | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04821284 Background | Dec 2021 → Oct 2025 overdue | pancreatic ductal adenocarcinoma | Flemming Forsberg | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07280377 Background | Oct 2021 → Jul 2027 expected | anal squamous cell carcinoma, pancreatic ductal adenocarcinoma | Oncolytics Biotech | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05121038 Background | Oct 2021 → Sep 2025 overdue | colon carcinoma, malignant pancreatic neoplasm | Anup Kasi | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05083481 Background | Oct 2021 → May 2026 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05027386 Background | Aug 2021 → Feb 2026 overdue | neuroblastoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05004116 Background | Aug 2021 → Aug 2028 expected | metastatic neoplasm | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04901702 Comparator | Jun 2021 → Dec 2026 expected | Ewing sarcoma, Wilms tumor, hepatoblastoma, malignant germ cell tumor +5 | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04929652 Background | Jun 2021 → Jun 2022 | colorectal cancer | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04431258 Background | May 2021 → Jan 2024 | malignant pancreatic neoplasm | Ability Pharmaceuticals SL | Completed | No outcome recorded |
| Phase 1/2 | NCT04689347 Background | Jan 2021 → Apr 2026 overdue | colorectal cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04581473 Comparator | Oct 2020 → Oct 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm | CARsgen Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04522284 Background | Aug 2020 → Aug 2023 | cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT04337879 Background | Jul → Dec 2020 | colorectal cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04095221 Background | Sep 2019 → Feb 2025 | desmoplastic small round cell tumor, rhabdomyosarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04368507 Background | Aug 2019 → Dec 2021 | colorectal cancer | CellabMED | Completed | No outcome recorded |
| Phase 1/2 | NCT03829410 Background | Jun 2019 → Jan 2024 | colorectal cancer | Cardiff Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03828799 Background | May 2019 → Dec 2021 | colorectal cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1/2 | NCT03879798 Background | Mar 2019 → May 2023 | small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03722108 Comparator | Feb 2019 → May 2022 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | UNICANCER | Terminated | No outcome recorded |
| Phase 1/2 | NCT03607643 Background | Jan 2019 → Jun 2020 | colon carcinoma, gallbladder cancer, glioblastoma, liver cancer +3 | Leaf Vertical Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03699319 Background | Dec 2018 → Sep 2024 | pancreatic ductal adenocarcinoma | David Bajor, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT03545711 Background | May 2018 → Nov 2019 | colorectal cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT03526835 Background | May 2018 → Nov 2025 overdue | colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +2 | Merus B.V. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03263429 Background | Aug 2017 → Aug 2023 | colorectal cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03009058 Background | May → Aug 2017 | metastatic malignant neoplasm | Immodulon Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT02866903 Background | May 2017 → Mar 2019 | peritoneal carcinomatosis | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Phase 1/2 | NCT02568046 Background | Mar 2016 → May 2017 | colorectal cancer | Symphogen A/S | Terminated | No outcome recorded |
| Phase 1/2 | NCT02620865 Background | Dec 2015 → Jun 2021 | pancreatic adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02244632 Background | Sep 2014 → Jan 2020 | colorectal neoplasm | Isofol Medical AB | Completed | No outcome recorded |
| Phase 1/2 | NCT01959139 Background | Jan 2014 → Apr 2019 | pancreatic adenocarcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT01837862 Background | Oct 2013 → Apr 2024 | anaplastic astrocytoma, diffuse intrinsic pontine glioma, gliosarcoma, optic nerve glioma +2 | Julie Krystal | Completed | No outcome recorded |
| Phase 1/2 | NCT02025881 Background | Sep 2013 → Oct 2020 | medulloblastoma | Gustave Roussy, Cancer Campus, Grand Paris | Terminated | No outcome recorded |
| Phase 1/2 | NCT01505608 Background | Dec 2011 → Dec 2014 | neuroblastoma | Giselle Sholler | Terminated | No outcome recorded |
| Phase 1/2 | NCT01347645 Background | Sep 2011 → Jun 2015 | colon carcinoma, rectal carcinoma | Eisai Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01178411 Background | Aug 2010 → Jan 2019 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01133990 Background | Mar 2010 → Feb 2011 | colorectal cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01085331 Background | Mar 2010 → Apr 2012 | colorectal cancer | EMD Serono | Terminated | No outcome recorded |
| Phase 1/2 | NCT01075048 Background | Jan 2010 → Oct 2012 | colorectal cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/2 | NCT01008475 Background | Oct 2009 → Apr 2015 | colorectal cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/2 | NCT00954512 Background | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00594984 Comparator | May 2008 → Dec 2012 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT00551421 Background | Oct 2007 → Nov 2010 | colon adenocarcinoma, rectum adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00522665 Comparator | Aug 2007 → May 2011 | colorectal cancer | Hoosier Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT00361244 Background | Jul 2006 → Oct 2007 | colorectal carcinoma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT00217711 Comparator | May 2005 → Aug 2007 | colorectal cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00990912 Comparator | Jan 2004 → Nov 2005 | childhood malignant neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT00264134 Background | Jun 2003 → Oct 2005 | non-small cell lung carcinoma | Kentuckiana Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00005818 Background | Mar 2000 → Mar 2003 | colon adenocarcinoma, rectum adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2257 trials | ||||||
| Phase 2 | NCT07359456 Background | Aug 2026 → Aug 2029 expected | colorectal cancer | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07662031 Background | Aug 2026 → Aug 2030 expected | colorectal cancer | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07622771 Background | Jun 2026 → Jun 2028 expected | rectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07616362 Comparator | Jun 2026 → Apr 2029 expected | pancreatic ductal adenocarcinoma | Federation Francophone de Cancerologie Digestive | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07283705 Background | May 2026 → Oct 2029 expected | pancreas disorder | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Show all 257 trials opens the full record — a long page | ||||||
| Phase 2/313 trials | ||||||
| Phase 2/3 | NCT07585279 Comparator | May 2026 → Feb 2031 expected | colorectal cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07490301 Comparator | Apr 2026 → Jun 2031 expected | pancreatic ductal adenocarcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07549321 Background | Mar 2026 → Mar 2031 expected | neuroblastoma | Renaissance Pharma Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06079346 Comparator | May 2024 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | Oncotelic Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05427383 Background | Apr 2022 → Nov 2025 overdue | gastric cancer | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04749108 Background | Nov 2021 → Aug 2026 overdue | rectal carcinoma | Institut du Cancer de Montpellier - Val d'Aurelle | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02942706 Comparator | Nov 2021 → Oct 2022 | colorectal cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03686254 Comparator | Jul 2018 → Oct 2023 | colorectal cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02978313 Comparator | Nov 2016 → Nov 2019 | colorectal cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03031444 Comparator | Jan 2016 → Dec 2020 | colorectal cancer, metastatic neoplasm | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00952029 Background | Mar 2010 → Dec 2015 | colorectal cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 2/3 | NCT01550055 Comparator | May 2009 → Dec 2012 | colorectal cancer | Shanghai Zhangjiang Biotechnology Limited Company | Completed | No outcome recorded |
| Phase 2/3 | NCT00639327 Comparator | Mar 2008 → Apr 2011 | gastric cancer | Japan Clinical Cancer Research Organization | Completed | No outcome recorded |
| Phase 3115 trials | ||||||
| Phase 3 | NCT07621601 Comparator | Jul 2026 → Dec 2030 expected | esophageal squamous cell carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07271355 Background | Jul 2026 → Feb 2031 expected | appendix carcinoma, peritoneal carcinomatosis | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07595913 Comparator | Jul 2026 → Jun 2028 expected | neuroendocrine carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07582315 Comparator | Jul 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07621718 Background | May 2026 → Dec 2028 expected | pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Show all 115 trials opens the full record — a long page | ||||||
| Phase 411 trials | ||||||
| Phase 4 | NCT07094893 Background | Apr 2026 → Mar 2028 expected | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07020468 Background | May → Jul 2025 overdue | colorectal cancer | Affiliated Cancer Hospital of Shantou University Medical College | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06269445 Background | Jan 2024 → Feb 2025 | colorectal cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04810585 Background | Apr 2020 → Oct 2025 | colorectal cancer | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03645187 Comparator | Aug 2018 → Aug 2025 | colon carcinoma | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT01588990 Background | Jun 2012 → Sep 2016 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT01315990 Background | Jan 2011 → Mar 2015 | colorectal cancer | Dr. Carl Schimanski | Unknown | No outcome recorded |
| Phase 4 | NCT00808184 Comparator | Apr 2010 → Feb 2012 | neoplasm | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 4 | NCT00510627 Comparator | Aug 2007 → Dec 2010 | liver cancer | Boston Scientific Corporation | Withdrawn | No outcome recorded |
| Phase 4 | NCT01564810 Background | Sep 2006 → Jun 2012 | colorectal adenocarcinoma, metastatic malignant neoplasm | Xu jianmin | Unknown | No outcome recorded |
| Phase 4 | NCT02582970 Background | May 2005 → Oct 2007 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07325214 Background | Sep 2026 → Jan 2030 expected | malignant pancreatic neoplasm, pancreatic exocrine neoplasm | IMGT Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT07552402 Comparator | Jun 2026 → Dec 2027 expected | gastroesophageal junction adenocarcinoma | Harbin Medical University | Recruiting | No outcome recorded |
| — | NCT07044362 Background | Jun 2025 → Oct 2026 expected | liver cancer, metastasis from malignant tumor of colon | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| — | NCT06867146 Comparator | Oct 2024 → Dec 2026 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Active not recruiting | No outcome recorded |
| — | NCT06055179 Background | Mar 2024 → Jun 2026 overdue | irinotecan toxicity | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT05601323 Background | Jan 2023 → May 2027 expected | pancreas disorder | SONIRE Therapeutics Inc. | Active not recruiting | No outcome recorded |
| — | NCT05262452 Background | Aug 2021 → Mar 2023 | chemotherapy-induced toxicity, malignant pancreatic neoplasm | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT04926545 Background | Jul 2021 → Jul 2024 | cancer, diarrheal disease | Guangzhou University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT04276090 Background | May 2020 → Jan 2022 | bile duct neoplasm, colorectal neoplasm | Michael J Cavnar, MD | Terminated | No outcome recorded |
| — | NCT03690323 Background | Apr 2015 → Nov 2019 | pancreatic exocrine neoplasm | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| — | NCT01941173 Background | Jan → Jul 2014 | rectal cancer | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04446793 Background | — | colorectal cancer | Cardiff Oncology | No longer available | No outcome recorded |
Press releases naming this drug 16 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-31 | Ipsen | Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma ipsen.com ↗ |
| 2024-02-13 | Ipsen | Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA ipsen.com ↗ |
| 2023-06-14 | Ipsen | Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma ipsen.com ↗ |
| 2023-06-14 | Ipsen | Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma ipsen.com ↗ |
| 2023-01-20 | Ipsen | Ipsen presents Phase III NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI ipsen.com ↗ |
| 2022-11-09 | Ipsen | Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma ipsen.com ↗ |
| 2022-08-03 | Ipsen | Ipsen announces results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer ipsen.com ↗ |
| 2020-11-30 | Ipsen | Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC) ipsen.com ↗ |
| 2020-07-01 | Ipsen | Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer ipsen.com ↗ |
| 2020-06-17 | Ipsen | Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®) as a first-line combination treatment for metastatic pancreatic cancer ipsen.com ↗ |
| 2019-09-08 | Ipsen | Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer ipsen.com ↗ |
| 2019-07-05 | Ipsen | Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer ipsen.com ↗ |
| 2016-10-18 | Takeda | Shire Granted EU Marketing Authorization of ONIVYDE®, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV), For The Treatment of Metastatic Adenocarcinoma Of The Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy takeda.com ↗ |
| 2016-07-25 | Takeda | ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy takeda.com ↗ |
| 2008-02-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Generic Camptosar® tevapharm.com ↗ |
| 2007-08-29 | Daiichi Sankyo | Deal for Irinotecan Hydrochloride with Yakult Honsha Terminates daiichisankyo.com ↗ |
Evidence & citations 56 cited values
Every value below carries the sentence it was read from. 1,857 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan | “Patients with colorectal adenocarcinoma (CRC) received a single administration of 0.6 milligrams (mg) / kilograms (kg) of BI 905711 intravenously on Day 3 of each 14-day cycle....” NCT05087992 ↗1668“Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to...” NCT05959356 ↗ “Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2...” NCT00778830 ↗ “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Carboplatin; * Irinotecan; * Etoposide; *...” NCT03632135 ↗ “Patients were randomly assigned (1:1; block size of three), without stratification, to receive FOLFIRI (irinotecan 180 mg/m2, calcium folinate 400 mg/m2 or levofolinate 200...” PMID 36739879 ↗ Feb 2023 “Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT),...” NCT06841159 ↗ “It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400...” NCT01124630 ↗ “mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes,...” NCT03099265 ↗ “The FOLFOXIRI chemotherapy regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) will be administered according to the study protocol as part of total neoadjuvant...” NCT07277842 ↗ “Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous...” NCT01446458 ↗ “Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil +...” NCT05978349 ↗ “The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗ “Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV...” NCT04084496 ↗ “irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous...” NCT05004350 ↗ “Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the...” NCT01178411 ↗ “After completing 2 cycles of treatment, they were sequentially given liposomal irinotecan combined with 5-FU/LV, oxaliplatin (administered once every 2 weeks, with 4 weeks as...” NCT07208539 ↗ “The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the...” NCT03042780 ↗ “After first-line treatment of FOLFOX/FOLFIRI/FOLFOXIRI plus Cetuximab failure and defined as RAS/BRAF wild-type by molecular detection of cycle tumor DNA, the patients will be...” NCT04224415 ↗ “Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Irinotecan 150mg/m2+Capecitabine 1250mg/m2 for 6-8cycles, Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Capecitabine 1250mg/m2 as maintenance...” NCT06973343 ↗ “FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be...” NCT04446793 ↗ “irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a...” NCT01068132 ↗ “NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous...” NCT06429904 ↗ “FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2...” NCT00339183 ↗ “A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous...” NCT01333709 ↗ “The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400...” NCT05768503 ↗ “Therapy consisted of intravenous administration of RRx-001 at 4 mg once weekly for up to 2 months, at which point RRx-001 was discontinued, followed by intravenous infusion of...” PMID 36529613 ↗ Dec 2022 “BACKGROUND: FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with...” PMID 32921581 ↗ Jun 2020 “The regimen tested consisted of bevacizumab (5 mg/kg), folinic acid(400 mg/m²), 5-fluorouracil (2400 mg/m² for 46 h), oxaliplatin (85 mg/m²) and irinotecan (70 mg/m²...” PMID 39913183 ↗ Feb 2025 “IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine...” NCT01237665 ↗ “FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour...” NCT06278454 ↗ “The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and...” NCT06233877 ↗ “D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over...” NCT05065801 ↗ “Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose),...” NCT04185883 ↗ “Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil,...” NCT01505530 ↗ “Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan,...” NCT05132504 ↗ “The objective of this study was to evaluate safety and anti-tumour activity of fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) as salvage treatment in...” PMID 31919404 ↗ Jan 2020 “Patients with an unresectable metastatic colorectal carcinoma (mCRC) histologically proven will be treated with a combination of...” NCT02173990 ↗ “Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days;...” NCT03975049 ↗ “Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan,...” NCT06665087 ↗ “FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m²,...” NCT00508404 ↗ “All patients will be planned for six two-weekly cycles of FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) prior to chemoradiotherapy (25 × 2 Gy or 28 × 1.8...” PMID 36068495 ↗ Sep 2022 “G-FLIP regimen is a combination of low doses (doses lower than those approved by the FDA and used in the clinic) of several anti-cancer drugs, Gemcitabine, Fluorouracil,...” NCT01905150 ↗ “irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or...” NCT01328171 ↗ “An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be...” NCT04749108 ↗ “Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or...” NCT02350530 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks...” NCT05571644 ↗ “Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or...” NCT02063529 ↗ “Thirty-two patients with unresectable stage IIIA/B NSCLC received irinotecan (30 mg/m) and carboplatin dosed to a target area under the concentration curve of 2, each...” PMID 20357618 ↗ Apr 2010 “the objective of this protocol is to use a triple therapy based on 5FU and oxaliplatin associated to irinotecan which is administered by hepatic intra-arterial route, loaded...” NCT01839877 ↗ “A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal...” PMID 23406728 ↗ Feb 2013 “Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer:...” PMID 38181312 ↗ Jan 2024 “In the experimental arm, patients will be treated with irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion...” NCT06501482 ↗ “Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat...” NCT03193814 ↗ “Irinotecan liposome (nal-IRI) is a concentrate of an infusion solution containing 5 mg/ml irinotecan trihydrate (irinotecan sucrose salt) active substance, which is...” NCT06375642 ↗ “irinotecan 180 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT07359456 ↗ “FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV...” NCT01836432 ↗ “The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day...” NCT06099951 ↗ “FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each...” NCT05983367 ↗ “Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or...” NCT03398291 ↗ “There will be six groups: 1) combination with paclitaxel, 2) combination with topotecan, 3) combination with doxorubicin, 4) combination with 5-fluorouracil, folinic acid, and...” NCT06840886 ↗ “After dissolving 100 mg of irinotecan in water for injection or 4 ml of 5% glucose water. use 2 mL of 70 μm uniform particle size microspheres for loading and adsorption for 5 minutes.” NCT06177288 ↗ “Investigator-selected chemotherapy includes injectable taxanes (paclitaxel injection, albumin-bound paclitaxel, docetaxel, etc.), irinotecan, etc., excluding oral paclitaxel solution.” NCT07552402 ↗ “Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks.” NCT03875781 ↗ “Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma” PMID 25287828 ↗ Oct 2014 “The dose of irinotecan will be 125 mg/m2 for subjects not on Cytochrome P450, family 3, subfamily A (CYP3A)-inducing anti-epileptics (EIAEDs) and 340 mg/m2 for subjects on EIAEDs.” NCT00953121 ↗ “Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)” NCT04276090 ↗ “In 2011, the PRODIGE trial has shown that oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was associated with a survival advantage but had increased toxicity.” NCT06249321 ↗ “mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles” NCT05954078 ↗ “A Phase I Dose Escalation Study With Sunitinib (SutentR) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer” NCT00777478 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles” NCT04338191 ↗ “FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV)” NCT04389086 ↗ “The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.” NCT00821990 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)” NCT05200299 ↗ “FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle” NCT03391843 ↗ “Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated” NCT01839799 ↗ “the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death” NCT03787251 ↗ “Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.” NCT02004262 ↗ “Patients with colon cancer will receive systemic chemotherapy that will consist of either FOLFIRI, FOLFOX, or Irinotecan/oxaliplatin at the discretion of the oncologist.” NCT07201519 ↗ “FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours)” NCT01298570 ↗ “(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging” NCT06197425 ↗ “FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours).” NCT06640166 ↗ “Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours.” NCT01454180 ↗ “cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks” NCT04687631 ↗ “Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.” NCT06396091 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1)” NCT05427669 ↗ “continuous intravenous infusion of fluorouracil 2400mg / m², for 46 hours, leucovorin 400mg / m², irinotecan 135mg / m², and oxaliplatin 68mg / m², every 2 weeks” NCT06888648 ↗ “Patients also receive irinotecan IV over 30-90 minutes, leucovorin calcium IV over 5-10 minutes, and fluorouracil IV over 5-10 minutes on days 1, 8, 15, and 22.” NCT00021281 ↗ “The doses of other drug in the XELIRI regimen (irinotecan) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care.” NCT04522284 ↗ “Sorafenib is used in combination with irinotecan, leucovorin and fluorouracil in patients with advanced colorectal cancer after failure of oxaliplatin treatment” NCT00839111 ↗ “FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2)” NCT01564810 ↗ “Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week” NCT05665023 ↗ “Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion” NCT01888978 ↗ “Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus” NCT00265850 ↗ “Irinotecan 125 mg/m2 (not taking enzyme-inducing anti-epileptic drugs (EIAEDs)) or 340 mg/m2 (taking EIAEDs) given every two weeks on days 1, 15, 29, etc.;” NCT00735436 ↗ “HIPEC with irinotecan will be performed (a dose of 300 mg/m2 body surface area will be administered over 45 minutes at a temperature of 42 degrees Celsius)” NCT04597294 ↗ “Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA” NCT07472868 ↗ “FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours” NCT05360732 ↗ “Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w” NCT05634590 ↗ “This study will use a modified FOLFIRINOX (NALIRINOX) regimen with a form of irinotecan attached to liposomes that allows greater action on tumor cells.” NCT04010552 ↗ “mFOLFIRINOX- IV oxaliplatin 85 mg/m2; IV leucovorin 400 mg/m2; IV irinotecan 150 mg/m2; 5-FU 2400 mg/m2 by 46-hour infusion, per local standard of care” NCT07280377 ↗ “NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hours, liposomal irinotecan 50 mg/m2, and oxaliplatin 60 mg/m2, which would be given on Day 1 and Day 15” NCT07163273 ↗ “FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗ “oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1” NCT04781270 ↗ “FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1” NCT05399394 ↗ “5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]” NCT04952753 ↗ “Will receive a combination of BMS-986504, and the combination treatment mFOLFIRINOX (oxaliplatin, irinotecan, and 5-fluorouracil) for 4-6 months.” NCT07283705 ↗ “Following administration of bevacizumab, patients received irinotecan 180 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid” NCT00636610 ↗ “Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.” NCT06747845 ↗ “mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle.” NCT04158349 ↗ “After progression, only 40 to 45% of patients will receive a second line chemotherapy which will include 5-fluoro-uracil (5FU) and irinotecan” NCT04325425 ↗ “Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)” NCT02580253 ↗ “FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and 5-fluorouracil (400 mg/m2 bolus then 2400 mg/m2 over 46 h))” NCT07155629 ↗ “with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute intravenous infusion through a Y-connector.” NCT06384560 ↗ “An Open-Labeled, Non-Randomized Phase I Study Of Flavopiridol Administered With Irinotecan (CPT-11) In Patients With Advanced Solid Tumors” NCT00006485 ↗ “FOLFIRI is a combination of three drugs: (leucovorian, fluorouracil, and irinotecan) used to treat advanced metastatic colorectal cancer.” NCT06867822 ↗ “90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks” NCT05480306 ↗ “Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN-38.” PMID 34750990 ↗ Nov 2021 “irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle” NCT02217020 ↗ “irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle” NCT03161574 ↗ “The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.” NCT03322995 ↗ “The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:” NCT02592395 ↗ “oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles” PMID 33862000 ↗ Apr 2021 “Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion” NCT05077800 ↗ “FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W” NCT03168607 ↗ “Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w” NCT05193292 ↗ “Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata.” NCT02015754 ↗ “The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle).” NCT01347645 ↗ “It consists of irinotecan, leucovorin, and fluorouracil (5-FU) administered sequentially over a 46-hour infusion period per cycle.” NCT07381309 ↗ “Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).” NCT03374852 ↗ “Irinotecan (CPT-11) is a potent anticancer drug under the class of camptothecins that is marketed under the trade name Camptosar.” NCT02250157 ↗ “5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.” NCT01472016 ↗ “* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle” NCT03563248 ↗ “Liposomal irinotecan: Initial dose of 50 mg/m²; if well tolerated, the dose will be increased to 70 mg/m² in subsequent cycles.” NCT07239622 ↗ “a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor” NCT06555003 ↗ “Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.” NCT05121038 ↗ “modified folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin will be administered at a protocol-defined dose” NCT06835569 ↗ “FOLFIRINOX (14-day cycle) included oxaliplatin (standard dose), folinic acid, fluorouracil and irinotecan (150 or 180mg/m²).” PMID 38987363 ↗ Jul 2024 “Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.” NCT03825861 ↗ “Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days” NCT06048146 ↗ “Patients received IROX (irinotecan 200 mg/m(2) plus oxaliplatin 85 mg/m(2)) or irinotecan alone (350 mg/m(2)) every 3 weeks.” PMID 18824706 ↗ Oct 2008 “Other types of combination regimens including e.g. irinotecan have so far failed to show benefit in the adjuvant situation.” NCT05289076 ↗ “FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.” NCT04929223 ↗ “capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days” NCT03974854 ↗ “The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes” NCT03874026 ↗ “The chemotherapeutic agents include Doxorubicin, Gemcitabine , Paclitaxel, 5 Fluorouracil , Oxaliplatin, and Irinotecan.” NCT07254091 ↗ “180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.” NCT01862003 ↗ “Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.” NCT05851924 ↗ “A Phase II Trial of Irinotecan (CPT-11) and Cyclosporine in Patients With 5-FU Refractory Advanced Colorectal Cancer” NCT00003950 ↗ “Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1” NCT06603376 ↗ “FOLFIRI regimen [leucovorin, 5-fluorouracil, and irinotecan] with/without bevacizumab on Days 1/15 of a 28-day cycle” PMID 38036720 ↗ Nov 2023 “Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²” NCT04570943 ↗ “IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis” NCT05262452 ↗ “Irinotecan (IRI, also known as CPT-11) is an important component in chemotherapy for metastatic colorectal cancer.” NCT07515963 ↗ “Irinotecan: Irinotecan should be given on the first day of chemotherapy at a dose of 180mg/m2 by intravenous drip.” NCT06269445 ↗ “irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks” NCT02423226 ↗ “PEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated in liposomes.” PMID 27871319 ↗ Nov 2016 “treated with irinotecan (50 mg/m2/d d1-5 Q3W) in combination with Anlotinib (12 mg Qd, 2 weeks on and 1 week off)” PMID 38310286 ↗ Feb 2024 “It is a combination of leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin” NCT06483555 ↗ “irinotecan - anti-cancer medication used to treat colon cancer in combination with other chemotherapeutic agents” NCT06896188 ↗ “Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.” NCT04469556 ↗ “calcium folinate 400 mg/m\^2 + irinotecan 135 mg/m\^2 + oxaliplatin 68 mg/m\^2 (day 1, 15, a total of 28 days).” NCT03633734 ↗ “a 2-hour hepatic arterial infusion of Oxaliplatin (85 mg/m²) and an infusion of Liposomal Irinotecan (70 mg/m²)” NCT07504471 ↗ “the control group (n=28) which received 6 cycles of folinic acid, fluorouracil and irinotecan (FOLFIRI) regimen” PMID 35022282 ↗ Jan 2022 “Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion” NCT04229004 ↗ “Chemotherapy (standard of care with first line therapy of base of 5-FU with either oxaliplatin or irinotecan).” NCT07044362 ↗ “Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.” NCT01526135 ↗ “Through a peritoneal access port, irinotecan will be administered at the same time as systemic (chemo)therapy” NCT07133490 ↗ “Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique.” NCT05277766 ↗ “Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.” NCT06867146 ↗ “Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle” NCT02178709 ↗ “BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1” NCT01071655 ↗ “Combination treatment may include: 5FU/LFA, capecitabine, oxaliplatin, irinotecan, bevacizumab, aflibercept” NCT07213570 ↗ “IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.” NCT06047379 ↗ “Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2” NCT03750669 ↗ “Irinotecan will be administered as a 180 mg/m2 intravenous infusion over 60 minutes (day 1) every 2 weeks.” NCT04425239 ↗ “Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days” NCT04793932 ↗ “Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil” NCT04380337 ↗ “mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.” NCT05968326 ↗ “Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)” NCT03329690 ↗ “Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle” NCT03511183 ↗ “oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals” NCT03443661 ↗ “Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day.” NCT03671252 ↗ “FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion” NCT05832398 ↗ “Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.” NCT06736717 ↗ “Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours” NCT05332002 ↗ “Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes.” NCT04926545 ↗ “tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan” NCT05143099 ↗ “Leucovorin 400 mg/m², 5-FU (bolus + continuous), irinotecan 180 mg/m², oxaliplatin 85 mg/m² IV Day 1” NCT07053150 ↗ “monotherapy chemotherapy (paclitaxel 175mg/m2 or docetaxel 75mg/m2 or irinotecan 270mg/m2, d1, q3w)” NCT07016737 ↗ “oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\]” NCT06149689 ↗ “FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus cetuximab induction therapy” PMID 37721754 ↗ Sep 2023 “receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy” NCT00806663 ↗ “Irinotecan chemotherapy (350 mg/m2) will be administered after the administration of panitumumab.” NCT00475293 ↗ “TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2）” NCT06423937 ↗ “The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes)” NCT02568046 ↗ “Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion” NCT05419479 ↗ “Irinotecan (Campto®): 180 mg/m² on D1 by IV infusion in 250 mL of 0.9% saline over 90 minutes.” NCT00467142 ↗ “use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles.” NCT03904927 ↗ “NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin)” NCT06816914 ↗ “oxaliplatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days” NCT06495463 ↗ “Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle” NCT00885885 ↗ “Four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.” NCT06438614 ↗ “Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1;” NCT02023593 ↗ “of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion” NCT02440958 ↗ “consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2).” NCT04594772 ↗ “BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate” NCT02697058 ↗ “FOLFIRINOX is comprised of four drugs: Oxaliplatin, irinotecan, fluorouracil and leucovorin.” NCT01821729 ↗ “FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)” NCT03022734 ↗ “intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle” NCT05929885 ↗ “FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks” NCT00208260 ↗ “Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle.” NCT00101894 ↗ “Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5” NCT01463982 ↗ “FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil.” NCT03597581 ↗ “This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).” NCT04683315 ↗ “Cetuximab with or without Irinotecan (for patients not previously treated with cetuximab).” NCT07353268 ↗ “IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours” NCT01358812 ↗ “5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.” NCT01946074 ↗ “Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2” NCT04986930 ↗ “Irinotecan Liposome: 70 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).” NCT06993025 ↗ “The treatment planned consisted of irinotecan 160 mg/m² in 250 ml of NaCl 0.9% over 1 hr” NCT05316818 ↗ “FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy” NCT06826092 ↗ “FOLFIRI regimen: irinotecan 180mg/m2 intravenous infusion for 30-90min on days 1 and 15” NCT07362836 ↗ “Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks” NCT01003964 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT05593328 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT06106308 ↗ “Oxaliplatin (65 mg/m\^2), Irinotecan (140 mg/m\^2), Leucovorin (400 mg/m\^2) on Day 1” NCT07312422 ↗ “Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV” NCT06360354 ↗ “Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.” NCT06252649 ↗ “Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy” NCT03772132 ↗ “Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin.” NCT00411450 ↗ “concurrently with Irinotecan (irinotecan at 140mg/m2 given as a 90 min IV infusion)” NCT03504423 ↗ “Folfirinox(Systemic Chemotheray based on Oxaliplatin，5-fluorouracil and Irinotecan)” NCT04398927 ↗ “Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.” NCT07702032 ↗ “Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1” NCT04835064 ↗ “Irinotecan: 135 mg/m² intravenous infusion over more than 30-90 minutes, on day 1;” NCT07469956 ↗ “Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle” NCT03511170 ↗ “FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1” NCT03485027 ↗ “FOLFIRI: Irinotecan 180mg/m², intravenous infusion for 30 to 90 minutes on day 1;” NCT07391618 ↗ “three active cytotoxic agents (Fluorouracil, Oxaliplatin, Irinotecan, FOLFOXIRI)” NCT02942563 ↗ “180 mg/m2 body-surface area \[BSA\] of irinotecan, intravenously \[IV\] on day 1” NCT02758951 ↗ “irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days” NCT01736904 ↗ “Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan” NCT00440310 ↗ “The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.” NCT03941093 ↗ “Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;” NCT04617821 ↗ “Irinotecan 180 mg/m2 (150 mg/m2 for older patient after SGA) for 1h30 on day 1.” NCT07616362 ↗ “oxaliplatin or irinotecan based regimens, according to the first line treatment” NCT04653480 ↗ “Escalation treatment (5FU + irinotecan + oxaliplatin [FOLFIRINOX] for 6 months)” NCT07340567 ↗ “infusions will consist of the drugs * 5-Fluorouracil * Irinotecan * Leucovorin” NCT03803553 ↗ “Ongericimab, Toripalimab, Bevacizumab, Irinotecan, Calcium folinate, 5-FU, Q2W” NCT07106034 ↗ “Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin” NCT03899636 ↗ “irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf” NCT00479583 ↗ “Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion” NCT03331640 ↗ “irinotecan 180 mg/m2 as per dose-level given as a 90-min intravenous infusion” NCT06757244 ↗ “Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.” NCT05794971 ↗ “neoadjuvant mFOLFIRINOX (5-Fluorouracil, oxaliplatin, leucovorin, irinotecan)” NCT07671339 ↗ “modified leucovorin, fluorouracil, irinotecan, and oxaliplatin [mFOLFIRINOX]” PMID 40184561 ↗ Apr 2025 “Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.” NCT01276379 ↗ “Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles” NCT00620269 ↗ “Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.” NCT01383538 ↗ “Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w” NCT03044587 ↗ “irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion” NCT07446322 ↗ “Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue” NCT02352337 ↗ “Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid” NCT02827201 ↗ “FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.” NCT04931420 ↗ “Liposomal Irinotecan free base via IV, predetermined dosage per protocol” NCT04656041 ↗ “FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles” NCT01703390 ↗ “Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium” NCT06572813 ↗ “a regimen combining 5-fluorouracil (5-FU), folinic acid, and irinotecan” PMID 19826418 ↗ Oct 2009 “Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.” NCT03185988 ↗ “Irinotecan 150 mg/m² infused via arterial pump over 90 minutes on day 1” NCT07024537 ↗ “irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1” NCT03635021 ↗ “Irinotecan, 150 mg/m² IV once every two weeks over 90 minutes on Day 1” NCT05825066 ↗ “Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)” NCT00972465 ↗ “oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2” NCT04230187 ↗ “Chemotherapeutic agents are limited to irinotecan or docetaxel alone.” NCT03547804 ↗ “mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU.” NCT02839343 ↗ “YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion” NCT04368507 ↗ “FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin)” PMID 32681477 ↗ Jul 2020 “* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg” NCT04089150 ↗ “5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab” PMID 31101691 ↗ May 2019 “Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes” NCT01640444 ↗ “Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes” NCT01640405 ↗ “irinotecan liposome combined with oxaliplatin + 5-FU/LV (NALIRIFOX)” NCT07020468 ↗ “Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1” NCT02125136 ↗ “Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin” NCT02355119 ↗ “FOLFOXIRI (Irinotecan 165mg/m², iv, d1; Oxaliplatin 85mg/m², iv, d1” NCT07070713 ↗ “liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV)” NCT02826486 ↗ “Irinotecan: 150 mg/m2 i.v. over 90 min every 42 days on D1, 15, 29” NCT05679050 ↗ “FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)” NCT01853813 ↗ “Irinotecan 180 mg/m², intravenous infusion over 90 minutes, Day 1” NCT07604909 ↗ “Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks” NCT03600623 ↗ “followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion” NCT01085331 ↗ “Cohort 2 (30 patients) : Fruquintinib combined with irinotecan .” NCT05928312 ↗ “Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,” NCT05462496 ↗ “FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) therapy” PMID 29800971 ↗ Jul 2018 “Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36” NCT01123811 ↗ “* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan” NCT06518538 ↗ “Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w” NCT02453490 ↗ “Either irinotecan or temozolomide or carboplatin or etoposide” NCT05718466 ↗ “5-Fu combined with irinotecan or oxaliplatin standard regimen” NCT03412994 ↗ “Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous” NCT01964287 ↗ “CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)” NCT06816771 ↗ “Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.” NCT05652894 ↗ “Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2” NCT05555901 ↗ “Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min” NCT01441349 ↗ “FOLFIRI [Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2” NCT03686254 ↗ “mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU” NCT05354817 ↗ “* irinotecan 180 mg/m2 IV over 90 minutes concurrently with” NCT05848739 ↗ “LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens” NCT03253133 ↗ “FOLFIRI：Irinotecan, 180 mg/m² IV over 30-90 minutes (Day 1)” NCT07021950 ↗ “FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil” NCT01133990 ↗ “Irinotecan 180mg/m2 intravenously over 90 minutes on day 1.” NCT01661088 ↗ “mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin” NCT06913218 ↗ “irinotecan 180 mg/m2, administered as 1.5-hour iv infusion” NCT04431258 ↗ “FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil” NCT03288987 ↗ “Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2” NCT05842525 ↗ “irinotecan hydrochloride IV over 2 hours on days 1 and 15” NCT01417494 ↗ “5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2” NCT05081687 ↗ “FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min” NCT01878422 ↗ “5FU, leucovorin, oxaliplatin, irinotecan and bevacizumab” NCT03401294 ↗ “cmFOLFOXIRI: oxaliplatin 85 mg/m² , irinotecan 150 mg/m²” NCT06890624 ↗ “oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV” NCT05083247 ↗ “IV administration of Irinotecan 135 mg/m2 for 90 minutes” NCT05257993 ↗ “IRIN - irinotecan (Camptosar), a topoisomerase inhibitor” NCT01523457 ↗ “Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes)” NCT02305758 ↗ “mXELIRI: capecitabine tablets plus irinotecan injection” NCT06513221 ↗ “irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1” NCT00752570 ↗ “Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.” NCT06648434 ↗ “irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days” NCT01576692 ↗ “Irinotecan, Oxaliplatin , fluorouracil, and leucovorin” NCT03812783 ↗ “FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab” NCT06525428 ↗ “Irinotecan \[20 mg/mL concentration; administered IV\]” NCT03798626 ↗ “combination of Fluorouracil, leucovorin and irinotecan” NCT02033551 ↗ “Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle” NCT06389760 ↗ “Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1” NCT02563002 ↗ “FOLFIRI (Irinotecan, 5-fluorouracil and Folinic Acid)” NCT02605044 ↗ “FOLFIRI:: irinotecan intravenously 180 mg/m2 on day 1” NCT07061080 ↗ “Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1” NCT00153998 ↗ “Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion” NCT00852228 ↗ “Irinotecan (D1) H+1: 180mg/m² IV infusion over 60min” NCT04392479 ↗ “with irinotecan infusion 180 mg/m\^2 for 90 minutes” NCT01827553 ↗ “Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1” NCT02591667 ↗ “mFOLFIRINOX (Oxaliplatin, Irinotecan, Fluorouracil)” NCT03891472 ↗ “followed by irinotecan 180 mg/m2 i.v. in 60 minutes” NCT02162563 ↗ “Irinotecan will be administered 180 mg/m2 biweekly.” NCT03391934 ↗ “Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin” NCT05601323 ↗ “Folinic acid, Irinotecan, fluorouracil, oxaliplatin” NCT03822936 ↗ “* Irinotecan 150mg/m2 IV infusion over 60-90 min D1” NCT05534087 ↗ “Irinotecan: 180 mg/m², 90-120 min IV infusion on d1” NCT07004413 ↗ “oxaliplatin folinic acid irinotecan 5FU oxaliplatin” NCT02676349 ↗ “irinotecan plus E7820 in combination with cetuximab” NCT00309179 ↗ “5-fluorouracil, oxaliplatin, Irinotecan, leucovorin” NCT04292743 ↗ “D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min” NCT00313872 ↗ “irinotecan 180mg/m2 given as 90-minute IV infusion” NCT03690323 ↗ “Irinotecan 180 mg/m\^2 IV infusion over 90 minutes” NCT01571284 ↗ “Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1” NCT06242418 ↗ “Irinotecan: 150 mg/m2 IV infusion for over 1 hours” NCT04810585 ↗ “Topoisomerase 1 inhibitor: Topotecan or Irinotecan” NCT03257267 ↗ “Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab” NCT04380103 ↗ “FOLFIRI: Irinotecan, leucovorin and 5-flurouracil.” NCT00911170 ↗ “* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1” NCT01923987 ↗ “Irinotecan 165 mg/m², intravenous infusion, Day 1;” NCT07229846 ↗ “Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1” NCT03031444 ↗ “i. Docetaxel or ii. Irinotecan or iii. Paclitaxel” NCT06190782 ↗ “Irinotecan: 180 mg /m2 iv on day1, every 14 days.” NCT02439385 ↗ “Irinotecan 180 mg/m2 over a 90 minute IV infusion” NCT01488552 ↗ “FOLFIRI includes folic acid, 5-FU and irinotecan.” NCT06855849 ↗ “Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1” NCT01290783 ↗ “Irinotecan 150 mg/m2 IV over 90 minutes on Day 1” NCT04224402 ↗ “Irinotecan: 150mg/m2 IV over 90 min-14 day cycle” NCT05070104 ↗ “Irinotecan- 150 mg/m2, IV over 90 minutes, day 1” NCT05926206 ↗ “Irinotecan: 150 mg/m² IV over 90 minutes (Day 1)” NCT06575127 ↗ “Irinotecan: 150 mg/m², 90 min IV infusion on d1” NCT05008809 ↗ “irinotecan* 165 mg/m² iv continue for 1.5 hours” NCT05201430 ↗ “Irinotecan 180mg/m2 iv over 90 minutes on day 1” NCT02613650 ↗ “* Irinotecan: 180 mg/m² by 2-hour IV infusion,” NCT03959293 ↗ “Irinotecan 180 mg/m2 Intravenous (IV) on day 1” NCT04348045 ↗ “VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)” NCT05540951 ↗ “Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly.” NCT01366118 ↗ “5-fluorouracil (5-FU), leucovorin, irinotecan” NCT01322815 ↗ “Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2)” NCT02727387 ↗ “irinotecan 150 mg/m2 as a 90 minute infusion” NCT04672005 ↗ “escalating doses of sorafenib and irinotecan” NCT00780169 ↗ “3. Irinotecan, 150 mg/m2, IV over 90 minutes” NCT03603834 ↗ “Topoisomera 1 positive ( Topo-1): Irinotecan” NCT01453257 ↗ “Irinotecan : 180mg/m2 IV over 1.5-hr, day 1” NCT05103020 ↗ “Folinic Acid, 5-FU, Oxaliplatin, Irinotecan” NCT05466799 ↗ “Irinotecan 150 mg/m2 IV continuous infusion” NCT05174169 ↗ “Irinotecan Hydrochloride Liposome Injection” NCT07262567 ↗ “Irinotecan135-180mg/m2，iv, D1, 14days/cycle” NCT04324307 ↗ “Folinic acid, 5-FU, Irinotecan, Oxaliplatin” NCT06079346 ↗ “Irinotecan 180mg/m² as a 2-hour IV infusion” NCT06278545 ↗ “Irinotecan 180 mg/m² IV, 30 - 90 min day 1” NCT03688230 ↗ “FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU” NCT06621563 ↗ “* Fluorouracil * Irinotecan * Folinic acid” NCT04793958 ↗ “Irinotecan containing chemotherapy regimen” NCT00510627 ↗ “Irinotecan 180mg/m ² static pulse infusion” NCT05797883 ↗ “Irinotecan (IRI) - Starting dose 180 mg/m2” NCT02726334 ↗ “Irinotecan 180 mg/m\^2 IV over 90 minutes” NCT02405585 ↗ “Irinotecan:180 mg/m2 intravenous infusion” NCT02970916 ↗ “Irinotecan 180 mg/m2 day 1 i.v. 30-90 min” NCT01704703 ↗ “IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1” NCT03487939 ↗ “IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1” NCT03484221 ↗ “Irinotecan 180 mg/m² iv , 90 min on day 1” NCT01315990 ↗ “IRINOTECAN 165 mg/sqm IV over 1-h, day 1” NCT02271464 ↗ “5-fluorouracil + leucovorin + irinotecan” NCT01605344 ↗ “Irinotecan 150 mg/m\^2 IV over 1h, day 1” NCT03484195 ↗ “IRINOTECAN 165 mg/sqm IV over 1-h, day 1” NCT03085992 ↗ “Irinotecan 180 mg/m² for over 90 minutes” NCT02128100 ↗ “* Irinotecan: 180 mg/m² (IV/90 minutes)” NCT02591030 ↗ “Irinotecan 150 mg/m2 IV over 90 minutes” NCT06153368 ↗ “FOLFIRI (5-FU, irinotecan, leucovorin).” NCT02482441 ↗ “mFOLFIRI irinotecan 130-150mg/m2 iv d1” NCT01044420 ↗ “Irinotecan 180 mg/m2 I.V 30-90 min，D1；” NCT05362617 ↗ “Irinotecan (mg/m2) IV, over 30 minutes” NCT00200200 ↗ “Irinotecan 180 mg/m2 D1 90-minute I.V.” NCT02311439 ↗ “Irinotecan at 150 mg/m2 IV over 90 min” NCT04452461 ↗ “irinotecan (irinotecan hydrochloride)” NCT00316862 ↗ “Irinotecan 150 mg per square meter IV” NCT06048484 ↗ “Irinotecan 150 mg/m2 60-90 min day 1” NCT06899477 ↗ “Irinotecan：180 mg/m2, i.v. , d1, q2w” NCT05522738 ↗ “Irinotecan 165 mg/m2 over 90 minutes” NCT02581215 ↗ “1. Irinotecan at 2-weekly schedule.” NCT01832467 ↗ “Irinotecan, IV, D1 to D5, 50mg/m²/d” NCT03011528 ↗ “XELIRI (capecitabine + irinotecan)” NCT01531595 ↗ “Irinotecan 135mg/m2 IV infusion D1” NCT06151262 ↗ “Irinotecan: 180 mg/m² IV over 1H30” NCT03186326 ↗ “Irinotecan will be administered at” NCT05585320 ↗ “cisplatin and irinotecan given IV” NCT00381706 ↗ “FOLFIRI - Irinotecan 180 mg/m2 IV” NCT05721872 ↗ “Imatinib, Irinotecan, Ixabepilone” NCT02788201 ↗ “Irinotecan(Camptosar)150mg /m2 d1” NCT01964027 ↗ “XELIRI: Irinotecan 240 mg/m\^2 IV” NCT00127036 ↗ “Irinotecan: 200mg/m2 ivgtt d1 q3w” NCT05669092 ↗ “Irinotecan 180 mg/m2 IV on Day 1” NCT05733689 ↗ “irinotecan 150 mg/m2 intravenous” NCT05646511 ↗ “irinotecan (100 mg/m2, 0-2h, d2)” NCT06199232 ↗ “Irinotecan 180 mg/m2; i.v. bolus” NCT03081143 ↗ “3. Irinotecan-180 mg/m2 IV Day 1” NCT03291899 ↗ “irinotecan 150 mg/m2 over 90 min” NCT04611724 ↗ “Irinotecan 180 mg/m2 iv on day 1” NCT01543412 ↗ “* Irinotecan 150 mg/m2 IV day 1” NCT03885284 ↗ “5-FU, leucovorin and irinotecan” NCT03692429 ↗ “irinotecan (day 1; 180 mg/m(2))” PMID 25627002 ↗ Jan 2015 “FOLFIRI (180 mg/m\^2 irinotecan” NCT06936527 ↗ “Irinotecan 180 mg/sqm on day 1” NCT01219920 ↗ “Irinotecan+Nordic FLv (6 pat.)” NCT01379482 ↗ “Oxaliplatin, Irinotecan, 5-FU.” NCT02148549 ↗ “irinotecan 165 mg/m² IV day 1” NCT04423965 ↗ “Irinotecan 150 mg/m2 IV day 1” NCT05179889 ↗ “irinotecan 180 mg/m², Q3W, D1” NCT07446387 ↗ “irinotecan (150 mg/m2; day 1)” NCT06242067 ↗ “Imatinib Irinotecan Lapatinib” NCT02551718 ↗ “Irinotecan, 200mg/m², Q3W, D1” NCT07289997 ↗ “Irinotecan165mg/m2 IV day 1” NCT05353582 ↗ “Gemcitabine with irinotecan” NCT01726582 ↗ “Irinotecan IV 180 mg/m2 D1” NCT02749136 ↗ “irinotecan IV on days 1, 8” NCT00349492 ↗ “irinotecan 180mg/m2，iv ，d1” NCT01486992 ↗ “Irinotecan Leucovorin FU” NCT05605509 ↗ “* Irinotecan (180 mg/m2)” NCT01688336 ↗ “Irinotecan (180 mg/m\^2)” NCT01595321 ↗ “irinotecan 150 mg/m2 D1” NCT05066802 ↗ “* irinotecan: 180 mg/m²” NCT03879109 ↗ “IV Irinotecan 150 mg/m2” NCT05194878 ↗ “Irinotecan 150-180mg/m2” NCT07284277 ↗ “* irinotecan: 180 mg/m²” NCT02514278 ↗ “Irinotecan IV + 5-FU IV” NCT02866903 ↗ “irinotecan 150mg/m2, d1” NCT04908566 ↗ “* Irinotecan (FOLFIRI)” NCT03251612 ↗ “irinotecan - Camptosar” NCT00819754 ↗ “irinotecan\* 135 mg/m²” NCT04170530 ↗ “180 mg/m\^2 irinotecan” NCT03829410 ↗ “irinotecan 180 mg/m\^2” NCT03806309 ↗ “Irinotecan (Camptosar)” NCT01260415 ↗ “Irinotecan (Camptosar)” NCT00856830 ↗ “irinotecan + platinum” NCT00391586 ↗ “Irinotecan 180 mg/m2.” NCT06501989 ↗ “irinotecan, 150 mg/m2” NCT02028806 ↗ “NUC-3373 + irinotecan” NCT03428958 ↗ “irinotecan 135mg/m\^2” NCT03977272 ↗ “Irinotecan liposomes” NCT07074353 ↗ “Irinotecan 150 mg/m²” NCT06813976 ↗ “irinotecan (CPT-11)” NCT00008060 ↗ “campto (irinotecan)” NCT00251888 ↗ “irinotecan (CPT-11)” NCT00808184 ↗ “irinotecan (CPT-11)” PMID 19457245 ↗ May 2009 “Irinotecan+LV5FU2” NCT02978313 ↗ “Irinotecan+LV5FU2” NCT02942706 ↗ “Drug: Irinotecan” NCT03872947 ↗ “Drug: Irinotecan” NCT00256269 ↗ “Drug: Irinotecan” NCT02641873 ↗ “Drug: Irinotecan” NCT04525014 ↗ “Drug: Irinotecan” NCT04095221 ↗ “Drug: Irinotecan” NCT01014767 ↗ “Irinotecan” NCT02063529 ↗ “Irinotecan” NCT04215731 ↗ “Irinotecan” NCT03117972 ↗ “Irinotecan” NCT04169347 ↗ “irinotecan” NCT02241551 ↗ “Irinotecan” NCT01703910 ↗ “Irinotecan” NCT04553692 ↗ “Irinotecan” NCT02128425 ↗ “Irinotecan” NCT06846346 ↗ “Irinotecan” NCT05421897 ↗ |
| Known as | Aili | “Irinotecan monotherapy (trade name: Aili; batches 180103AG” NCT02030678 ↗ |
| Known as | BAX2398 | “BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate” NCT02697058 ↗ |
| Known as | Campt, Topotesin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00209612 ↗ |
| Known as | Campto | “A Multicenter Randomized Phase II Study Evaluating The Activity And Tolerability Of Three Different Combinations Of Docetaxel (Taxotere) And Irinotecan (Campto) As Second Line...” NCT00139711 ↗12“A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable...” NCT00635323 ↗ “Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.” NCT01526135 ↗ “Irinotecan (Campto®): 180 mg/m² on D1 by IV infusion in 250 mL of 0.9% saline over 90 minutes.” NCT00467142 ↗ “Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study” NCT04088604 ↗ “180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes” NCT00561470 ↗ “irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes” NCT02967289 ↗ “Nexavar (Sorafenib) and irinotecan (Campto)” NCT00989469 ↗ “Irinotecan = Camptosar, Campto, or CPT-11” NCT00996346 ↗ |
| Known as | Camptosar | “The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as...” NCT00037180 ↗19“irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous...” NCT05004350 ↗ “Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas,...” NCT00381797 ↗ “A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors” NCT00186979 ↗ “A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract” NCT00020761 ↗ “Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).” NCT03374852 ↗ “Phase II Study for the Evaluation of CPT-11 (Irinotecan, Camptosar) in Patients With Metastatic or Recurrent Breast Cancer” NCT00004182 ↗ “irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.” NCT06047379 ↗ “180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes” NCT00561470 ↗ “Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1” NCT01523431 ↗ “IRIN - irinotecan (Camptosar), a topoisomerase inhibitor” NCT01523457 ↗ “irinotecan (also known as CPT-11, Camptosar)” NCT00040391 ↗ “Irinotecan = Camptosar, Campto, or CPT-11” NCT00996346 ↗ “Irinotecan(Camptosar)150mg /m2 d1” NCT01964027 ↗ “Irinotecan (Camptosar, CPT-11)” NCT00283556 ↗ “IRI (irinotecan \[CAMPTOSAR\])” NCT03184870 ↗ “irinotecan - Camptosar” NCT00819754 ↗ “Irinotecan (Camptosar)” NCT01260415 ↗ |
| Known as | Camptothecin-11 | “irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous...” NCT05004350 ↗ |
| Known as | CPT-11 | “PURPOSE: The aims of this trial were to assess the safety and efficacy of two different dosing schedules of irinotecan (CPT-11) in recurrent glioma patients, to assess...” PMID 19066728 ↗ Dec 200875“The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as...” NCT00037180 ↗ “irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous...” NCT05004350 ↗ “We hypothesized that germline polymorphisms within genes related to drug target (thymidylate synthase) or metabolizing enzymes (UDP-glucuronosyltransferase, UGT) would impact...” PMID 15709193 ↗ Feb 2005 “This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects...” NCT00165464 ↗ “A Phase I/II Study to Evaluate Safety and Efficacy in Patients Who Have Resectable Esophageal Cancer and Are Treated With Neoadjuvant Cisplatin, Irinotecan (CPT-11) ZD1839...” NCT00290719 ↗ “We had previously demonstrated that low dose irinotecan (CPT-11) leads to increased accumulation of cells in S-phase and shows a therapeutic synergy with S-phase specific...” PMID 18594219 ↗ Aug 2008 “Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use...” NCT00817284 ↗ “Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for...” NCT00003835 ↗ “nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug...” NCT03328884 ↗ “A Phase I Study to Evaluate Orally Administered Irinotecan HCL (CPT-11) Given as a Powder-Filled Capsule Formulation Daily for 14 Days Every Three Weeks in Patients With...” NCT00004051 ↗ “This study was conducted to determine the maximum tolerated dose and dose-limiting toxicity of irinotecan (CPT-11) administered every 3 weeks to adults with progressive malignant glioma” PMID 14769140 ↗ Jan 2004 “Irinotecan (CPT-11,7-ethyl-10-\[4-(1-piperidino)-1-piperidino\] is a semi-synthetic plant alkaloid obtained from Camptotheca acuminate of the Nyssaceae family.” NCT01138904 ↗ “A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors” NCT00186979 ↗ “Determine the maximum tolerated dose of ICI D1694 (TDX) when given with irinotecan (CPT-11) every 3 weeks in patients with advanced solid malignancies.” NCT00002902 ↗ “A Phase II Trial of Radiotherapy Combined With Raltitrexed and Irinotecan(CPT-11) in Patients With Metastatic or Locally Recurrent Colorectal Cancer” NCT04499586 ↗ “Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas” NCT00544778 ↗ “A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma” PMID 18417462 ↗ Apr 2008 “An Open-Labeled, Non-Randomized Phase I Study Of Flavopiridol Administered With Irinotecan (CPT-11) In Patients With Advanced Solid Tumors” NCT00006485 ↗ “CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks” NCT01212718 ↗ “Irinotecan (CPT-11) is a potent anticancer drug under the class of camptothecins that is marketed under the trade name Camptosar.” NCT02250157 ↗ “Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer” NCT00209625 ↗ “more recently it has been given using neoadjuvant chemotherapy with intravenous irinotecan hydrochloride (CPT-11) and cisplatin.” NCT04789941 ↗ “Irinotecan (also known as CPT-11) was recently approved by the U.S. Food and Drug Administration (FDA) for use in colon cancer” NCT00183807 ↗ “Phase II Study for the Evaluation of CPT-11 (Irinotecan, Camptosar) in Patients With Metastatic or Recurrent Breast Cancer” NCT00004182 ↗ “For patients with ≥ Grade 1 toxicity will allow 84 days prior to beginning therapy with Avastin and Irinotecan (CPT-11).” NCT00735436 ↗ “CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)” NCT00346801 ↗ “A Phase II Study of Irinotecan (CPT-11) and Docetaxel (Taxotere) in Patients With Recurrent Non-Small Cell Lung Cancer” NCT00003900 ↗ “A Phase II Trial of Irinotecan (CPT-11) and Cyclosporine in Patients With 5-FU Refractory Advanced Colorectal Cancer” NCT00003950 ↗ “Irinotecan (IRI, also known as CPT-11) is an important component in chemotherapy for metastatic colorectal cancer.” NCT07515963 ↗ “A PHASE I STUDY OF IRINOTECAN (CPT-11) WITH PHARMACOKINETIC MODULATION BY CYCLOSPORINE A AND PHENOBARBITAL” NCT00002759 ↗ “Irinotecan (CPT-11) is approved in metastatic colorectal cancer treatment and can cause severe toxicity.” PMID 17510208 ↗ May 2007 “treatment with the drugs irinotecan (also known as CPT-11) and docetaxel (also known as Taxotere)” NCT00183872 ↗ “Irinotecan (CPT-11) is a promising camptothecin analogue with activity in solid tumors.” NCT00001495 ↗ “two irinotecan (CPT-11), fluorouracil (FU), leucovorin (LV), and oxaliplatin schedules” PMID 12963697 ↗ Sep 2003 “Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks” NCT01640782 ↗ “Phase II Evaluation of Irinotecan (CPT-11) in Previously Treated Advanced Sarcomas” NCT00003719 ↗ “Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks.” NCT00003137 ↗ “CPT-11 (irinotecan), leucovorin (folinic acid), and 5-Fluorouracil (5-FU)” NCT00265850 ↗ “two other chemotherapy drugs, called Irinotecan (CPT-11) and Cisplatin.” NCT00215995 ↗ “Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.” NCT03167112 ↗ “With Irinotecan (CPT-11) (NSC- #6616348) Plus Temodar (NSC #362856)” NCT00005951 ↗ “Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).” PMID 11489791 ↗ Aug 2001 “Irinotecan (CPT-11) is a new drug active in colorectal cancer.” PMID 9654118 ↗ 1998 “Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics” NCT00006103 ↗ “Panitumumab + CPT11 (irinotecan hydrochloride)” NCT00655499 ↗ “irinotecan (also known as CPT-11, Camptosar)” NCT00040391 ↗ “Irinotecan hydrochloride hydrate (CPT-11)” NCT02497157 ↗ “Irinotecan = Camptosar, Campto, or CPT-11” NCT00996346 ↗ “Plus Irinotecan (CPT-11) (NSC 616348)” NCT00612638 ↗ “Irinotecan (Camptosar, CPT-11)” NCT00283556 ↗ “Irinotecan (CPT-11) : 90mg/m²” NCT02640365 ↗ “Drug: Irinotecan (CPT-11)” NCT06897644 ↗ “Drug: Irinotecan (CPT-11)” NCT04668976 ↗ “Drug: Irinotecan (CPT-11)” NCT03693807 ↗ “irinotecan (CPT-11)” NCT00008060 ↗ “irinotecan (CPT-11)” PMID 19457245 ↗ May 2009 “Irinotecan (CPT-11)” NCT06760117 ↗ “Irinotecan (CPT-11)” NCT07094893 ↗ “Irinotecan (CPT-11)” NCT03069950 ↗ “Irinotecan (CPT-11)” NCT07056777 ↗ “Irinotecan (CPT-11)” NCT06733038 ↗ “CPT-11” NCT00061932 ↗ |
| Known as | CPT-11:Irinotecan | “CPT-11:Irinotecan” NCT01424709 ↗ |
| Known as | HE072 | “This study (NCT04728035) aimed to explore the safety and efficacy of liposomal irinotecan (HE072) in patients with metastatic triple-negative breast cancer (mTNBC).” PMID 39746964 ↗ Jan 2025 |
| Known as | HR070803 | “This randomized, double-blind, parallel-controlled, multicenter phase 3 study (NCT05074589) assessed the efficacy and safety of liposomal irinotecan HR070803 combined with...” PMID 39300077 ↗ Sep 20242“Jiangsu Hengrui Pharmaceutical Co., Ltd. developed irinotecan hydrochloride liposome injection (HR070803) has both protection Protective, long-term cyclic and passively targeted.” NCT06531278 ↗ “Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.” PMID 39037543 ↗ Jul 2024 |
| Known as | IRI | “the aim of the present NEXIRI-2/PRODIGE 27 trial was to assess the 2-month non-progression rate for sorafenib (NEX) plus irinotecan (IRI), that is, NEXIRI, treatment.” PMID 32737004 ↗ May 20209“FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗ “FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle” NCT03403101 ↗ “Leucovorin calcium (folinic acid)(FOL) + fluorouracil \[F\] + irinotecan \[IRI\]” NCT00551213 ↗ “bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide” PMID 29121274 ↗ Jun 2018 “Irinotecan (IRI) - Starting dose 180 mg/m2” NCT02726334 ↗ “Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1;” NCT04160416 ↗ “Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1” NCT04508452 ↗ “irinotecan (Iri) at progression” PMID 34507244 ↗ Sep 2021 |
| Known as | Irinotecan (campto, CPT-11) | “Irinotecan (campto, CPT-11)” NCT00166881 ↗ |
| Known as | Irinotecan (Camptosar) | “Irinotecan (Camptosar)” NCT02568046 ↗3“Irinotecan, Camptosar®” NCT00003950 ↗ “Irinotecan (Camptosar)” NCT02178709 ↗ “Irinotecan (Camptosar)” NCT00856830 ↗ |
| Known as | Irinotecan (CPT-11) | “Irinotecan (CPT-11)” NCT02624726 ↗ |
| Known as | Irinotecan (drug) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07150247 ↗ |
| Known as | Irinotecan (irinotecan HCl, CPT-11 or Campto, Aventis) | “Irinotecan (irinotecan HCl, CPT-11 or Campto®, Aventis)” NCT00153998 ↗ |
| Known as | Irinotecan Cell pharm | “Irinotecan (Irinotecan Cell pharm®)” NCT02085148 ↗ |
| Known as | irinotecan HCL | “A Phase I Study to Evaluate Orally Administered Irinotecan HCL (CPT-11) Given as a Powder-Filled Capsule Formulation Daily for 14 Days Every Three Weeks in Patients With...” NCT00004051 ↗1“Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5” NCT01463982 ↗ |
| Known as | Irinotecan hydrochloride | “OBJECTIVES:
I. To define the maximally tolerated dose of the combination of CPT-11 (irinotecan hydrochloride), oxaliplatin, and capecitabine in three different populations,...” NCT00074321 ↗184“To evaluate the objective response rate systemically and in the CNS to the combination of irinotecan hydrochloride and temozolomide among patients with breast cancer and...” NCT00617539 ↗ “This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic...” NCT00433550 ↗ “Patients receive mFOLFIRINOX comprising oxaliplatin intravenously (IV) over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and...” NCT02047474 ↗ “Patients received modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of...” PMID 27275632 ↗ Aug 2016 “This phase II trial studies the side effects and how well irinotecan hydrochloride, oxaliplatin and cetuximab work in treating patients with unresectable or metastatic...” NCT00871169 ↗ “Patients receive irinotecan hydrochloride IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2 (FOLFIRI).” NCT00537121 ↗ “Patients receive bevacizumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.” NCT00628810 ↗ “To determine the dose-limiting toxicity and maximum tolerated dose of irinotecan hydrochloride according to the genotype status of Asian patients with solid tumors.” NCT00731276 ↗ “To evaluate the safety and efficacy of irinotecan (irinotecan hydrochloride) in breast cancer patients with brain metastases who progressed after radiation therapy.” NCT01939483 ↗ “neoadjuvant dose-dense chemotherapy comprising doxorubicin hydrochloride, ifosfamide, and irinotecan hydrochloride in combination with dexrazoxane hydrochloride” NCT00544778 ↗ “single-agent irinotecan hydrochloride (Ir) vs Ir with cyclosporine (IrC) in patients with fluorouracil-resistant advanced colorectal cancer.” NCT00389870 ↗ “Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata.” NCT02015754 ↗ “Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata.” NCT03175016 ↗ “more recently it has been given using neoadjuvant chemotherapy with intravenous irinotecan hydrochloride (CPT-11) and cisplatin.” NCT04789941 ↗ “Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8.” NCT00275041 ↗ “treated with the combination of irinotecan hydrochloride and trastuzumab (Herceptin®) after prior first- or second-line therapy” NCT00303992 ↗ “Patients receive dose-dense induction chemotherapy comprising irinotecan hydrochloride IV and cisplatin IV on days 1 and 8.” NCT00616785 ↗ “patients receive carboplatin IV over 30 minutes followed by irinotecan hydrochloride IV over 90 minutes on day 1.” NCT00449020 ↗ “Patients receive irinotecan hydrochloride IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1” NCT00416767 ↗ “Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector” NCT01771146 ↗ “panitumumab is administered in combination with irinotecan hydrochloride as third-line therapy” NCT00655499 ↗ “FOLFIRI chemotherapy comprising irinotecan hydrochloride, fluorouracil, and leucovorin calcium” NCT00524186 ↗ “fluorouracil, and irinotecan \[irinotecan hydrochloride\]” NCT01941173 ↗ “irinotecan hydrochloride IV over 90 minutes on day 1” NCT00303771 ↗ “Drug: irinotecan hydrochloride Given IV” NCT03641976 ↗ “Drug: irinotecan hydrochloride” NCT00080951 ↗ “Drug: irinotecan hydrochloride” NCT00112658 ↗ “Drug: irinotecan hydrochloride” NCT00952029 ↗ “Drug: irinotecan hydrochloride” NCT00003351 ↗ “Drug: Irinotecan Hydrochloride” NCT06995872 ↗ “Drug: irinotecan hydrochloride” NCT00012220 ↗ “Drug: irinotecan hydrochloride” NCT00003134 ↗ “Drug: irinotecan hydrochloride” NCT00072527 ↗ “Drug: irinotecan hydrochloride” NCT00098787 ↗ “Drug: irinotecan hydrochloride” NCT00045162 ↗ “Drug: irinotecan hydrochloride” NCT00012363 ↗ “Drug: irinotecan hydrochloride” NCT00138216 ↗ “Drug: irinotecan hydrochloride” NCT00005076 ↗ “Drug: irinotecan hydrochloride” NCT00079352 ↗ “Drug: irinotecan hydrochloride” NCT00003995 ↗ “Drug: irinotecan hydrochloride” NCT00469898 ↗ “Drug: irinotecan hydrochloride” NCT00042939 ↗ “Drug: irinotecan hydrochloride” NCT00005036 ↗ “Drug: irinotecan hydrochloride” NCT00004139 ↗ “Drug: Irinotecan Hydrochloride” NCT04215159 ↗ “Drug: irinotecan hydrochloride” NCT00588900 ↗ “Drug: irinotecan hydrochloride” NCT00052494 ↗ “Drug: Irinotecan Hydrochloride” NCT04094688 ↗ “Drug: irinotecan hydrochloride” NCT00016952 ↗ “Drug: irinotecan hydrochloride” NCT00134069 ↗ “Drug: irinotecan hydrochloride” NCT00003748 ↗ “Drug: Irinotecan Hydrochloride” NCT02573220 ↗ “Drug: irinotecan hydrochloride” NCT00077285 ↗ “Drug: irinotecan hydrochloride” NCT00004919 ↗ “Drug: Irinotecan Hydrochloride” NCT04205968 ↗ “Drug: irinotecan hydrochloride” NCT00003900 ↗ “Drug: irinotecan hydrochloride” NCT00020761 ↗ “Drug: irinotecan hydrochloride” NCT00004235 ↗ “Drug: Irinotecan Hydrochloride” NCT04927780 ↗ “Drug: irinotecan hydrochloride” NCT00002759 ↗ “Drug: Irinotecan Hydrochloride” NCT06197438 ↗ “Drug: irinotecan hydrochloride” NCT00003835 ↗ “Drug: irinotecan hydrochloride” NCT00089102 ↗ “Drug: irinotecan hydrochloride” NCT00089128 ↗ “Drug: irinotecan hydrochloride” NCT00063960 ↗ “Drug: irinotecan hydrochloride” NCT00066781 ↗ “Drug: Irinotecan Hydrochloride” NCT04641871 ↗ “Drug: irinotecan hydrochloride” NCT00026195 ↗ “Drug: irinotecan hydrochloride” NCT00066612 ↗ “Drug: Irinotecan Hydrochloride” NCT00354835 ↗ “Drug: irinotecan hydrochloride” NCT00109850 ↗ “Drug: Irinotecan hydrochloride” NCT02246049 ↗ “Drug: irinotecan hydrochloride” NCT00027612 ↗ “Drug: Irinotecan Hydrochloride” NCT04535401 ↗ “Drug: irinotecan hydrochloride” NCT00217711 ↗ “irinotecan hydrochloride” NCT00005607 ↗ “irinotecan hydrochloride” NCT00004005 ↗ “irinotecan hydrochloride” NCT00087282 ↗ “irinotecan hydrochloride” NCT00075738 ↗ “irinotecan hydrochloride” NCT00026273 ↗ “irinotecan hydrochloride” NCT00005951 ↗ |
| Known as | Irinotecan hydrochloride hydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02497157 ↗ |
| Known as | Irinotecan hydrochloride liposome Injection | “Jiangsu Hengrui Pharmaceutical Co., Ltd. developed irinotecan hydrochloride liposome injection (HR070803) has both protection Protective, long-term cyclic and passively targeted.” NCT06531278 ↗3“Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk” NCT06128837 ↗ “Irinotecan hydrochloride liposome injection: 70mg/m2, intravenous infusion” NCT06467786 ↗ “Drug: Irinotecan Hydrochloride Liposome Injection” NCT06499610 ↗ |
| Known as | Irinotecan hydrochloride trihydrate | “Irinotecan hydrochloride trihydrate is...” NCT04390399 ↗2“Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.” NCT03175016 ↗ “Drug: Irinotecan hydrochloride trihydrate” NCT00160875 ↗ |
| Known as | Irinotecan hydrochloride: CPT-11 | “Irinotecan hydrochloride: CPT-11” NCT00546130 ↗ |
| Known as | Irinotecan liposoma | “Drug: Irinotecan liposoma” NCT06782685 ↗ |
| Known as | Irinotecan Liposomal | “Drug: Irinotecan Liposomal” NCT06782685 ↗ |
| Known as | Irinotecan liposome | “Drug: Irinotecan Liposome Irinotecan liposome injection will be administered by an intravenous infusion at the dose of 50 mg/m\^2, d1, 14 days per cycle.” NCT07309289 ↗15“irinotecan liposome 60 mg/m2, iv, for at least 90 minutes” NCT05969899 ↗ |
| Known as | Irinotecan Liposome Injection | “Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion.” NCT04083235 ↗1“Drug: Irinotecan Liposome Injection” NCT04728035 ↗ |
| Known as | irinotecan liposome(II) | “Drug: irinotecan liposome(II) 70mg/m\^2, IV, D1, Q3W” NCT06820762 ↗ |
| Known as | Irinotecan Monohydrochloride Trihydrate | “Irinotecan Monohydrochloride Trihydrate” NCT02095132 ↗ |
| Known as | irinotecan sucrosofate | “irinotecan sucrosofate (liposomal irinotecan)” NCT06821997 ↗ |
| Known as | Irinotecan-Camptosar-CPT 11 | “Irinotecan - Camptosar - CPT11” NCT00616005 ↗1“Irinotecan-Camptosar-CPT 11” NCT00612638 ↗ |
| Known as | Irinotecan-CPT 11-Camptosar | “Irinotecan, (CPT 11),(Camptosar®)” NCT00931840 ↗1“Irinotecan-CPT 11-Camptosar” NCT00611728 ↗ |
| Known as | IRN | “This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (NIR) with temozolomide (TMZ; arm 1) or irinotecan (IRN; arm 2) in patients with pretreated ES.” PMID 33289920 ↗ Dec 20201“irinotecan [IRN]” PMID 20530282 ↗ Jun 2010 |
| Known as | Liposomal irinotecan | “NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous...” PMID 37708904 ↗ Sep 202327“Liposomal Irinotecan in Combination With Oxaliplatin and Bevacizumab Versus Liposomal Irinotecan in Combination With 5-FU/LV for the Second-line Treatment of Advanced Pancreatic Cancer” NCT06782685 ↗ “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ “Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.” PMID 39037543 ↗ Jul 2024 “RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.” PMID 38648575 ↗ Apr 2024 “NALIRIFOX: Oxaliplatin 85 mg/m2, D1; Liposomal irinotecan 60 mg/m2, D1; LV 200 mg/m2; 5-FU 2400 mg/m2, Infusion for 48 hours” NCT07622771 ↗ “Liposomal irinotecan is a form of the anticancer drug irinotecan that is contained inside very tiny, fat-like particles.” NCT06821997 ↗ “liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI)” NCT03861702 ↗ “Liposomal irinotecan is irinotecan encapsulated by liposomes, which has advantages in safety.” NCT06462105 ↗ “All patients receiving NALIRIFOX initiated liposomal irinotecan at the full starting dose.” PMID 42080361 ↗ May 2026 “Drug: Liposomal irinotecan” NCT05854498 ↗ “Drug: Liposomal Irinotecan” NCT05255666 ↗ |
| Known as | Liposomal Irinotecan Hydrochloride Injection (II) | “Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1” NCT06603376 ↗ |
| Known as | Liposome irinotecan | “Liposome irinotecan(50mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle” NCT07376499 ↗ |
| Known as | LY01610 | “A Multicenter, Randomized, Open-label, Parallel-design Phase 3 Study to Evaluate the Efficacy and Safety of LY01610 (Irinotecan Hydrochloride Liposome Injection) Versus...” NCT06128837 ↗ |
| Known as | MM-398 | “nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug...” NCT03328884 ↗ |
| Known as | nal-IRI | “This prospective phase II, single arm, single site trial will evaluate the efficacy of the combination of liposomal irinotecan (nal-IRI), TAS102, and bevacizumab for the...” NCT05854498 ↗12“This is a Phase I and Early Efficacy Study of Convection Enhanced Delivery (CED) of irinotecan liposome injection (nal-IRI) Using Real Time Imaging with Gadolinium in Children...” NCT03086616 ↗ “We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in...” PMID 33284237 ↗ Feb 2021 “Liposomal Irinotecan (Nal-IRI) Plus 5-fluorouracil and Leucovorin (5-FU/LV) Plus Oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients With Advanced Small Intestine...” NCT07060014 ↗ “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ “liposomal irinotecan (Nal-IRI) is a novel nanoliposome formulation of irinotecan that accumulates in tumor-associated macrophages improving the therapeutic index of irinotecan” PMID 33403007 ↗ Sep 2020 “Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique.” NCT05277766 ↗ “liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI)” NCT03861702 ↗ “Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate” NCT06700603 ↗ “Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w” NCT03044587 ↗ “substituting liposomal irinotecan (nal-IRI) for nonliposomal irinotecan” PMID 37753702 ↗ Sep 2023 “Liposomal Irinotecan (nal-IRI)” NCT05251038 ↗ “nal-IRI (ONIVYDE®)” NCT03703063 ↗ |
| Known as | nal-irinotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04617457 ↗ |
| Known as | nal-irinotecan (nal-iri) | “nal-irinotecan (nal-iri)” NCT04617457 ↗ |
| Known as | Nanoliposomal CPT-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00734682 ↗ |
| Known as | nanoliposomal irinotecan | “Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk” NCT05385861 ↗ |
| Known as | NSC-616348 | “Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)” NCT00045162 ↗1“A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors” NCT00708773 ↗ |
| Known as | Onivyde | “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗10“Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique.” NCT05277766 ↗ “Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid” NCT03528785 ↗ “liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV)” NCT02826486 ↗ “Irinotecan Liposomal Injection [Onivyde]” NCT03468335 ↗ “Irinotecan Liposomal Injection [Onivyde]” NCT04371224 ↗ |
| Known as | Onyvide | “nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)” NCT04617457 ↗ |
| Known as | pegylated nanoliposomal irinotecan | “We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in...” PMID 33284237 ↗ Feb 2021 |
| Known as | PEP02 | “nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug...” NCT03328884 ↗ |
| Known as | Topotesin | “Drug: Campto, Topotesin” NCT00209651 ↗1“Campto, Topotesin” NCT00316745 ↗ |
| Known as | U-101440E | “U-101440E” NCT02095132 ↗ |
| Known as | U101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07184827 ↗ |
| Action | Inhibit | “in vitro inhibition of topoisomerase I activity by irinotecan” NCT00002933 ↗ |
| Modality | Small molecule | “Irinotecan (CPT-11) is a promising camptothecin analogue” NCT00001495 ↗ |
| Route | Intravenous | “Patients receive cyclosporine IV over 6 hours and irinotecan IV over 90 minutes weekly for 4 weeks.” NCT00002759 ↗ |
| Target | TOP1 | “topoisomerase 1 (top1) inhibitor” NCT04514497 ↗ |